Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6

Journal of Viral Hepatitis

Volumn 17, Issue 10, 2010, Pages 691-697

  Nguyen, N H ^a,b   Vutien, P ^a,b   Garcia, R T ^a,c   Trinh, H ^a,c   Nguyen, H ^c   Nguyen, K ^c   Levitt, B ^c   Nguyen, M H ^b  

^a Pacific Health Foundation   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c San Jose Gastroenterology   (United States)

Author keywords

Asian Americans; genotype; HCV; sustained virologic response; treatment outcomes

Indexed keywords

ERYTHROPOIETIN; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASIAN AMERICAN; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; COUGHING; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GENOTYPE; GROUPS BY AGE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VOMITING;

ADULT; ANTIVIRAL AGENTS; ASIAN AMERICANS; BLOOD; CALIFORNIA; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77956624510     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01226.x     Document Type: Article

References (31)

1. National Institutes of Health. Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997 26 (3 Suppl. 1 2S 10S.
2. World Health organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999 74 (49 425 427.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 (10 705 714.
4. Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005 9 (3 411 426. vi.
5. Adams NJ, Chamberlain RW, Taylor LA et al. Complete coding sequence of hepatitis C virus genotype 6a. Biochem Biophys Res Commun 1997 234 (2 393 396.
6. Mizokami M, Gojobori T, Ohba K et al. Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes. J Hepatol 1996 24 (5 622 624.
7. Lao W. Prevalence of gnoetype 6 chronic hepatitis C infection in Hong Kong. J Gastroenterol Hepatol 2002 17: Abstract 142A.
8. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 2005 75 (4 538 549.
9. Lwin AA, Shinji T, Khin M et al. Hepatitis C virus genotype distribution in Myanmar: predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res 2007 37 (5 337 345.
10. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005 3 (10 Suppl. 2 S97 S101.
11. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
12. Hadziyannis SJ, Sette H Jr. , Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
14. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997 26 (3 Suppl. 1 122S 127S.
15. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995 22 (4 Pt 1 1050 1056.
16. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 (21 1485 1492.
17. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002 36 (5 Suppl. 1 S114 20.
18. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002 36 (5 1259 1265.
19. Fung J, Lai CL, Hung I et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008 198 (6 808 812.
20. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003 187 (7 1071 1074. (Pubitemid 36399349)
21. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008 103 (5 1131 1135.
22. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999 29 (4 1311 1316.
23. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999 30 (3 787 793.
24. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994 91 (17 8239 8243.
25. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996 34 (9 2259 2266.
26. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004 117 (3 163 168.
27. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008 47 (10 1260 1269.
28. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007 102 (10 2181 2188.
29. Yan KK, Guirgis M, Dinh T et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008 14 (21 3416 3420.
30. Kuboki M, Iino S, Okuno T et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007 22 (5 645 652.
31. Fancher TL, Ton H, Le Meyer O, Ho T, Paterniti DA. Discussing depression with Vietnamese American patients. J Immigr Minor Health 2009 [epub ahead of print].